ArticleJournal of carcinogenesis2011
Oncogenic activation of ERG: A predominant mechanism in prostate cancer.
Article in Journal of carcinogenesis, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 57 citations in OpenAlex.
- mRNA Isoforms and Variants in Health and Disease.International journal of molecular sciences · 2025Review
- Targeting Prostate Cancer Metabolism Through Transcriptional and Epigenetic Modulation: A Multi-Target Approach to Therapeutic Innovation.International journal of molecular sciences · 2025Review
- Distinct mesenchymal cell states mediate prostate cancer progression.Nature communications · 2024Article
- Biomarkers of Aggressive Prostate Cancer at Diagnosis.International journal of molecular sciences · 2023Review
- The Expression of Proto-OncogeneInternational journal of molecular sciences · 2022Review
- ACE2: At the crossroad of COVID-19 and lung cancer.Gene reports · 2021Review
- Activation of TC10-Like Transcription by Lysine Demethylase KDM4B in Colorectal Cancer Cells.Frontiers in cell and developmental biology · 2021Article
- FGviewer: an online visualization tool for functional features of human fusion genes.Nucleic acids research · 2020Article
- Strong cytoplasmic ETV1 expression has a negative impact on prostate cancer outcome.Virchows Archiv : an international journal of pathology · 2019Article
- TMPRSS2-ERG fusions linked to prostate cancer racial health disparities: A focus on Africa.The Prostate · 2019Article
- A Rich Array of Prostate Cancer Molecular Biomarkers: Opportunities and Challenges.International journal of molecular sciences · 2019Review
- Article
- Corpora amylacea in prostatectomy tissue and associations with molecular, histological, and lifestyle factors.The Prostate · 2018Article
- Ethnic differences in TGFβ-signaling pathway may contribute to prostate cancer health disparity.Carcinogenesis · 2018Article
- Synergistic Activity with NOTCH Inhibition and Androgen Ablation in ERG-Positive Prostate Cancer Cells.Molecular cancer research : MCR · 2017Article
- ETS Related Gene mediated Androgen Receptor Aggregation and Endoplasmic Reticulum Stress in Prostate Cancer Development.Scientific reports · 2017Article
- Racial disparities in prostate cancer: a molecular perspective.Frontiers in bioscience (Landmark edition) · 2017Review
- Autoantibodies against oncogenic ERG protein in prostate cancer: potential use in diagnosis and prognosis in a panel with C-MYC, AMACR and HERV-K Gag.Genes & cancer · 2016Article
- Prognostic value of ERG, PTEN, CRISP3 and SPINK1 in predicting biochemical recurrence in prostate cancer.Oncology letters · 2016Article
- Loss of miR-449a in ERG-associated prostate cancer promotes the invasive phenotype by inducing SIRT1.Oncotarget · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prevalent gene fusions involving regulatory sequences of the androgen receptor (AR) regulated genes (primarily TMPRSS2) and protein coding sequences of nuclear transcription factors of the ETS gene family (predominantly ERG) result in unscheduled androgen dependent ERG expression in prostate cancer (CaP).Cumulative data from a large number of studies in the past six years accentuate ERG alterations in more than half of all CaP patients in Western countries. Studies underscore that ERG functions are involved in the biology of CaP. ERG expression in normal context is selective to endothelial cells, specific hematopoetic cells and pre-cartilage cells. Normal functions of ERG are highlighted in hematopoetic stem cells. Emerging data continues to unravel molecular and cellular mechanisms by which ERG may contribute to CaP. Herein, we focus on biological and clinical aspects of ERG oncogenic alterations, potential of ERG-based stratification of CaP and the possibilities of targeting the ERG network in developing new therapeutic strategies for the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.